RecruitingInterventional · Phase 4NCT03991169 ↗Pilot Pragmatic Clinical Trial of Oral Iron Therapy in Children With Chronic Kidney DiseaseOleh M. AkchurinPIInterventionDrug: Ferrous SulfateDatesApr 2019 – Dec 2028 (est.)
Active, not recruitingInterventional · Phase 3NCT05144256 ↗A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly Transfused, Followed by a 5-Year Open-label Extension PeriodSujit ShethPIInterventionDrug: Mitapivat · Drug: Mitapivat-matching placeboDatesJun 2022 – May 2024SponsorAgios Pharmaceuticals, Inc.Pediatric Pyruvate Kinase DeficiencyPediatric Hemolytic Anemia
RecruitingInterventional · Phase 2NCT06788691 ↗Efficacy of Luspatercept In Clonal Cytopenias of Uncertain SignificancePinkal DesaiPIInterventionDrug: LuspaterceptDatesMar 2025 – Feb 2027 (est.)SponsorWeill Medical College of Cornell UniversityCCUS Clonal Cytopenia of Undetermined SignificanceAnemiaLeukopenia+2 more
CompletedInterventional · Phase 3NCT02981407 ↗Myocardial Ischemia and TransfusionXuming DaiPIInterventionBiological: Red Blood Cell TransfusionDatesApr 2017 – May 2023· Results postedSponsorRutgers UniversityMyocardial InfarctionAnemia
TerminatedInterventional · Phase 2NCT04103645 ↗A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)Joseph M ScanduraPIInterventionDrug: VactosertibDatesNov 2019 – Jul 2024· Results postedSponsorWeill Medical College of Cornell UniversityMyeloproliferative Neoplasm
CompletedInterventional · Phase 1/2NCT04455841 ↗A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative DisordersEllen K. RitchiePIInterventionDrug: INCB000928 · Drug: ruxolitinibDatesMar 2021 – Apr 2025· Results postedSponsorIncyte CorporationAnemiaPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera Myelofibrosis
CompletedInterventional · Phase 2NCT04987489 ↗A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseSujit ShethPIInterventionDrug: Etavopivat tabletsDatesMar 2022 – Sep 2025SponsorForma TherapeuticsSickle Cell DiseaseThalassemia